-
1.发明公开THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO Ý3,2,1-IJ¨QUINOLINE COMPOUNDS 有权THERAPEUTIC的取代的HYDROPYRIDO [3,2,1-IJ]喹啉化合物
公开(公告)号：EP2294069A1
公开(公告)日：2011-03-16
申请号：EP09743667.9
申请日：2009-05-07
申请人： Allergan, Inc. , Sinha, Santosh C. , Bhat, Smita , Chow, Ken , Beard, Richard L. , Donello, John E. , Garst, Michael E.
发明人： SINHA, Santosh, C. , BHAT, Smita , CHOW, Ken , BEARD, Richard, L. , DONELLO, John, E. , GARST, Michael, E.
IPC分类号： C07D471/04 , C07D471/06 , C07D471/16 , A61P27/00 , A61P9/00 , A61K31/4745
CPC分类号： C07D471/06 , C07D471/04 , C07D471/16
摘要： Disclosed herein are compounds represented by the structural formula (I): therapeutic methods, compositions, and medicaments related thereto are also disclosed.
-
2.发明授权THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO[3,2,1-IJ]QUINOLINE COMPOUNDS 有权THERAPEUTIC的取代的HYDROPYRIDO [3,2,1-IJ]喹啉化合物
公开(公告)号：EP2294069B1
公开(公告)日：2015-09-02
申请号：EP09743667.9
申请日：2009-05-07
申请人： ALLERGAN, INC. , Sinha, Santosh C. , Bhat, Smita , Chow, Ken , Beard, Richard L. , Donello, John E. , Garst, Michael E.
发明人： SINHA, Santosh, C. , BHAT, Smita , CHOW, Ken , BEARD, Richard, L. , DONELLO, John, E. , GARST, Michael, E.
IPC分类号： C07D471/04 , C07D471/06 , C07D471/16 , A61P27/00 , A61P9/00 , A61K31/4745
CPC分类号： C07D471/06 , C07D471/04 , C07D471/16
-
3.发明公开DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY 有权具有RAR（γ-亚基）受体拮抗剂拮抗活性的混合二氢吡啶肟
公开(公告)号：EP1701934A2
公开(公告)日：2006-09-20
申请号：EP04815018.9
申请日：2004-12-21
申请人： ALLERGAN, INC.
IPC分类号： C07C251/48
CPC分类号： C07D335/06 , C07C251/48 , C07C2602/08 , C07C2602/10 , C07D215/12
摘要： Compounds of the formula where the variables have the values described in the specification are antagonists of RARϜ retinoid receptors.
摘要翻译： 其中变量具有说明书中描述的值的式（I）化合物是RARβ类维生素A受体的拮抗剂。
-
4.发明公开DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS 审中-公开RARG类维生素A二取代CHALCONOXIME AS选择性激动剂
公开(公告)号：EP1704139A1
公开(公告)日：2006-09-27
申请号：EP04815251.6
申请日：2004-12-21
申请人： ALLERGAN, INC.
IPC分类号： C07C251/40 , C07D215/22 , C07D241/42 , C07D307/81 , C07D307/87 , C07D311/58 , C07D335/06 , A61K31/15 , A61K31/343 , A61K31/353 , A61K31/382 , A61K31/4704 , A61K31/498 , A61P11/00 , A61P17/06
CPC分类号： C07D307/87 , C07D215/227 , C07D335/06
摘要： Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARϜ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
-
5.发明公开METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B 审中-公开方法的处理对维甲酸吸引力与CYP26A和CYP26B的选择性抑制剂疾病
公开(公告)号：EP1696899A1
公开(公告)日：2006-09-06
申请号：EP04814113.9
申请日：2004-12-13
申请人： ALLERGAN, INC.
发明人： VASUDEVAN, Jayasree , YANG, Rong , WANG, Liming , LIU, Xiaoxia , TSANG, Kwok, Yin , LI, Ling , TAKEUCHI, Janet, A. , VU, Thong , BEARD, Richard, L. , BHAT, Smita , CHANDRARATNA, Roshantha, A.
IPC分类号： A61K31/19 , A61K31/35 , A61K31/38 , A61K31/192
CPC分类号： A61K31/19 , A61K31/192 , A61K31/35 , A61K31/38
摘要： The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
-
6.发明公开THERAPEUTICALLY USEFUL SUBSTITUTED 1, 7-DIPHENYL-L, 2, 3, 5, 6, 7-HEXAHYDROPYRIDO Ý 3, 2, 1-I J¨QUINOLINE COMPOUNDS 审中-公开THERAPEUTIC的取代的1,7-二苯基1,2,3,5,6,7-六氢吡啶并[3,2,1-IJ]喹啉化合物
公开(公告)号：EP2300468A1
公开(公告)日：2011-03-30
申请号：EP09743329.6
申请日：2009-05-01
申请人： Allergan, Inc.
IPC分类号： C07D471/04 , C07D471/06 , A61P9/00 , A61P27/00 , A61K31/4745
CPC分类号： C07D471/04 , C07D471/06
摘要： Disclosed herein are compounds represented by the structural formula I (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
-
7.发明授权DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY 有权分子式CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR（Gamma）-RETINOIDREZEPTOR
公开(公告)号：EP1701934B1
公开(公告)日：2009-02-25
申请号：EP04815018.9
申请日：2004-12-21
申请人： ALLERGAN, INC.
IPC分类号： C07C251/48
CPC分类号： C07D335/06 , C07C251/48 , C07C2602/08 , C07C2602/10 , C07D215/12
摘要： Compounds of the formula where the variables have the values described in the specification are antagonists of RARϜ retinoid receptors.
摘要翻译： 变量具有说明书中描述的值的式的化合物是RAR类视黄醇受体的拮抗剂。
-
8.发明公开COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME 审中-公开随着对恢复选择性细胞色素P450RAI-1或选择性细胞色素P450RAI 2抑制效果和方法链接
公开(公告)号：EP1699775A2
公开(公告)日：2006-09-13
申请号：EP04815022.1
申请日：2004-12-17
申请人： ALLERGAN, INC.
发明人： VASUDEVAN, Jayasree , WANG, Liming , LIU, Xiaoxia , TSANG, Kwok, Yin , LI, Ling , TAKEUCHI, Janet, A. , VU, Thong , BEARD, Richard, L. , BHAT, Smita , VULIGONDA, Vidyasagar , CHANDRARATNA, Roshantha, A.
IPC分类号： C07D311/96 , C07D311/64 , C07D311/58 , C07C59/64 , C07C229/46 , C07C59/86 , C07C229/34 , C07C69/753 , C07C69/18 , C07C275/42 , C07C229/38 , C07C69/76
CPC分类号： C07C69/73 , C07C57/42 , C07C59/64 , C07C59/86 , C07C69/753 , C07C69/76 , C07C229/34 , C07C229/38 , C07C229/46 , C07C229/50 , C07C275/42 , C07C2601/02 , C07C2602/10 , C07D311/58 , C07D311/64 , C07D311/96
摘要： Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
摘要翻译： 在本说明书中提供特异性抑制或选择性地要么细胞色素P450RAI一种酶或细胞色素P450RAI 2酶式1至17的化合物。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.025 秒)
